• Anti-Bromodeoxyuridine antibody [IIB5] (STJ16100807)
  • Anti-Bromodeoxyuridine antibody [IIB5] (STJ16100807)

Anti-Bromodeoxyuridine antibody [IIB5] (STJ16100807)

SKU:
STJ16100807-100

Shipping:
Free Shipping
Current Stock:
Host: Mouse
Applications: FC/IHC/IHC-F/IHC-P/ICC
Reactivity: Other
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-Bromodeoxyuridine is suitable for use in Flow Cytometry, Immunohistochemistry, Immunohistochemistry and Immunocytochemistry research applications.
Clonality: Monoclonal
Clone ID: IIB5
Conjugation: Unconjugated
Isotype: IgG1
Formulation: PBS with 0.09% sodium azide
Concentration: 1 mg/mL
Dilution Range: FC 1:100-1:200
IHC
IHC-F
IHC-P
Storage Instruction: Store at 2-8°C upon receipt.
Immunogen: BrdU conjugated to Bovine Serum albumin
Background The immunocytochemical detection of bromodeoxyuridine (BrdU) incorpoRated into DNA is a powerful tool to study the cytokinetics of normal and neoplastic cells. In vitro or in vivo labeling of tumor cells with the thymidine analogue BrdU and the subsequent detection of incorpoRated BrdU with specific anti-BrdU monoclonal antibodies is an accuRate and comprehensive method to quantitate the degree of DNA-synthesis. BrdU is incorpoRated into the newly synthezised DNA of the S-phase cells and can thus provide an estimate for the fraction of cells in S-phase. Also dynamic prolifeRative information (such as the S-phase transit Rate and the potential doubling time) can be obtained, by means of bivariate BrdU/DNA flow cytometric analysis. IIB5 reacts with bromodeoxyuridine (BrdU) also when incorporated into nuclear DNA.The antibody is known to cross-react with Iododeoxyuridine (IdU). Although we have no specific information concerning chlorodeoxyuridine (CldU) , it is to be expected that also this antigen is recognized by IIB5.

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance